Skip to main content
. 2024 Nov 27;13(11):6282–6297. doi: 10.21037/tcr-24-1860

Table 1. The clinical information of TCGA and CGGA.

Data TCGA (training set; N=669) CGGA (test set; N=1,018)
Age, years
   ≥60 146 (21.8) 116 (11.4)
   <60 463 (69.2) 902 (88.6)
   Unknown 60 (9.0)
Gender
   Male 355 (53.1) 417 (41.0)
   Female 254 (38.0) 601 (59.0)
   Unknown 60 (9.0)
OS (days) 537 (264.0–1,011.0) 836.5 (329.8–2,032.3)
State
   Alive 430 (64.3) 362 (35.6)
   Dead 239 (25.7) 617 (60.6)
   Unknown 39 (3.8)
IDH mutation status
   Wild type 233 (34.8) 435 (42.7)
   Mutant 429 (64.1) 531 (52.2)
   Unknown 7 (1.0) 52 (5.1)
1p19q codeletion status
   Codel 169 (25.3) 212 (20.8)
   Non-codel 494 (73.8) 728 (71.5)
   Unknown 6 (0.9) 78 (7.7)
MGMTp methylation status
   Methylated 477 (71.3) 472 (46.4)
   Un-methylated 161 (24.1) 376 (36.9)
   Unknown 31 (4.6) 170 (16.7)

Data are presented as n (%) or median (interquartile range). TCGA, The Cancer Genome Atlas; CGGA, Chinese Glioma Genome Atlas; OS, overall survival; IDH, isocitrate dehydrogenase; MGMT, O6-methylguanine DNA methyltransferase.